Complement Pharma Overview

  • Founded
  • 2009
  • Status
  • Acquired/​Merged
  • Employees
  • 1
  • Latest Deal Type
  • M&A

Complement Pharma General Information


Developer of monoclonal antibody intended to treat neurodegenerative and immune-mediated disorders. The company's monoclonal antibody targets the complement pathway in order to treat immune-mediated disorders, to accelerate nerve regeneration in neurological disorders and drug therapies for neurological disorders, enabling patients to get an early-stage drug that treats and meets the high unmet medical need.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Parent Company
Primary Office
  • Meibergdreef 9, K2 - 217
  • 1105 Amsterdam
  • Netherlands
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Complement Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 11-Jun-2018 00.000 Completed Generating Revenue
3. Corporate 01-Jan-2014 00000 00.000 Completed Generating Revenue
2. Debt - General 12-Oct-2011 $5M $5.9M Completed Generating Revenue
1. Seed Round 03-Dec-2010 $900K $900K Completed Generating Revenue
To view Complement Pharma’s complete valuation and funding history, request access »

Complement Pharma Executive Team (8)

Name Title Board Seat Contact Info
Robert Lamers Chief Executive Officer
Frank Baas Ph.D Chief Scientific Officer & Co-Founder
Kees Fluiter Ph.D Co-Founder
Valeria Ramaglia Ph.D Co-Founder
Lars Hedbys Ph.D Co-Founder
You’re viewing 5 of 8 executive team members. Get the full list »

Complement Pharma Board Members (3)

Name Representing Role Since
David Housman Ph.D Self Member of Supervisory Board 000 0000
Tom Schwarz Life Sciences Fund Amsterdam Member of Supervisory Board 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Complement Pharma Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Complement Pharma Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Life Sciences Fund Amsterdam Venture Capital Minority 000 0000 000000 0
Stichting ALS Nederland Corporation Minority 000 0000 000000 0
UvA Ventures Holding Accelerator/Incubator Minority 000 0000 000000 0
Ventac Partners Venture Capital Minority 000 0000 000000 0
To view Complement Pharma’s complete investors history, request access »